Median Technologies has secured a €40 million capital increase, potentially reaching €50 million, to fund the US and European deployment of its eyonis® LCS platform. This follow-on funding round aims to accelerate the development of new clinical indications for their proprietary pan-cancer early diagnosis platform. The specific investors were not detailed in the provided text.